ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics Inc

ADMA Biologics, Inc. (NASDAQ: ADMA) is facing a federal securities lawsuit after a short seller report and subsequent disclosures allegedly reveale...

ADMA Biologics Faces Federal Securities Lawsuit Over Alleged Channel Stuffing Scheme and Undisclosed Related Party Transactions 

Analysts are intrested in these 5 stocks: ( ($NTR) ), ( ($CAVA) ), ( ($CBRL) ), ( ($ADMA) ) and ( ($CRSP) ). Here is a breakdown of their recent


Nutrien, CAVA, Cracker Barrel, ADMA, CRISPR Trending With Analysts

ADMA Biologics ( ($ADMA) ) has provided an update. ADMA Biologics, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, where shareho...

Market Cap	$3.46B	P/E Ratio	10.13
52W High	$20.97	52W Low	$7.21
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	57.1%	52W Position	8.0%
Overall Score	58	Value Score	65
Quality Score	65	Technical Score	45

EPS Current Est	$0.82	EPS Next Est	$0.94
EPS Growth Est	+14.6%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADMA	$8.31	-1.31%	8.92M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ADMA	$8.31	-1.3%	8.92M
3
4
5
6

ADMA

ADMA

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ADMA Biologics Inc Data in Excel

Get ADMA Biologics Inc Data in Excel